UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $542,000 Stock Holdings in OmniAb, Inc. (NASDAQ:OABI)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its holdings in OmniAb, Inc. (NASDAQ:OABI) by 10.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 128,202 shares of the company’s stock after selling 15,434 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.11% of OmniAb worth $542,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in OABI. Towerview LLC increased its holdings in shares of OmniAb by 114.0% during the 2nd quarter. Towerview LLC now owns 535,000 shares of the company’s stock worth $2,006,000 after purchasing an additional 285,000 shares during the period. Isthmus Partners LLC raised its holdings in OmniAb by 37.2% in the 2nd quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock valued at $1,981,000 after acquiring an additional 143,387 shares in the last quarter. American Century Companies Inc. lifted its position in shares of OmniAb by 52.7% in the 2nd quarter. American Century Companies Inc. now owns 110,036 shares of the company’s stock worth $413,000 after acquiring an additional 37,963 shares during the period. Dimensional Fund Advisors LP boosted its stake in OmniAb by 6.9% during the second quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock worth $11,296,000 after buying an additional 194,835 shares in the last quarter. Finally, Sei Investments Co. raised its stake in shares of OmniAb by 11.0% in the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock valued at $109,000 after buying an additional 2,888 shares in the last quarter. 72.08% of the stock is owned by institutional investors.

OmniAb Stock Performance

OmniAb stock opened at $3.50 on Friday. The business’s fifty day moving average is $4.01 and its two-hundred day moving average is $4.17. The firm has a market cap of $494.26 million, a P/E ratio of -5.65 and a beta of -0.14. OmniAb, Inc. has a 52 week low of $3.43 and a 52 week high of $6.72.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on OABI shares. Benchmark reissued a “buy” rating and issued a $8.00 target price on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.